Dr Patrick Hughes
|Telephone||+61 8 8128 4843|
Dr. Hughes is interested in communication between the nervous and immune system, and particularly how this is relevant for gastrointestinal diseases. He collaborates with clinical gastroenterologists, immunologists and neuroscientists to investigate the effects immune mediators have on sensations from the gut, but also the effects neurotransmittors have on the immune system.
B. Sc. (Hons) 1999. PhD 2008
2014: Young Investigator Prize, United European Gastroenterology Week, Vienna Austria
2014: Invited member of GENIEUR (The Genes in Irritable Bowel Syndrome Research Network Europe), a pan European consortium. Dr. Hughes is the 1st Australian member.
NHMRC Australia Post-Doctoral Training Fellowship (mid 2010-mid 2014)
Young Investigator Award, Neurogastroenterology and Motility, 2013 USA.
Invitation to Little Brain Big Brain (restricted to 30 participants worldwide) Sept. 2012, Belgium
Travel Award, Neurogastroenterology and Motility, Nov. 2008. Switzerland
Travel Award, ANS, July 2007, Melbourne, Australia
Young Investigator Award, Neurogastroenterology and Motility, Sept. 2007 Korea.
RAH Medical Staff Society Research Prize. Best oral presentation. 2007.
Best poster award, School of Molecular Bioscience, University of Adelaide, 2006.
Young Investigator Award, Neurogastroenterology and Motility, Sept 2006. Boston
Travel Award, ANS, 2006, Sydney, Australia
Multiple projects are available to investigate how the nervous and immune system communicate using techniques related to both immune and nervous function in human tissue samples and animal models of colonic inflammation. Please contact Dr. Hughes if interested in this field.
2016-2019: NHMRC R.D. Wright Biomedical Fellowship
2015-2017: NHMRC projecct grant 1085080 "Faecal Microbiota Transplantation for Active
Ulcerative Colitis - a randomised controlled trial: clinical, microbial & immune outcomes". $675,986. 2015-2017. Andrews, Hughes, Conlon, Roberts-Thompson, Costello (CIB)
2013-2015: NHMRC project grant 1042952 “Immune activation in functional gastrointestinal disorders”. $454,369.21. 2013-2015. CIA (Sole CI).
2010-2014: NHMRC Biomedical Training Fellowship 614805 “Viscerosensory neuroimmune interactions”. $285,000. 2010-2014. CIA
2011-2013: NHMRC project grant 1008100 “Ion channels underlying inflammatory and postinflammatory visceral mechanical hypersensitivity” $436,299. 2011-2013. AI
Other competitive funding schemes:
2015: RAH clinical research grant. "Cognitive Behavioural Therapy moudlates the immune system in Inflammatory Bowel Disease patients" $32,000 CIA.
2014: RAH clinical research grant. "Identification of genetic pathways involved in immune activation in Irritable Bowel Syndrome" $35,000. CIA
2012: University of Adelaide Faculty of Health Science New Investigator grant “Immune activation in acute and relapsing colitis” 2012. CIA
2012: RAH clinical project grant “Immune activation in functional gastrointestinal disorders – a pilot study” 2012 CIA
2011: Princess Alexandra Hospital Research Foundation and Private Practice Trust Fund. “The role of the gastrointestinal tract microbiota and chronic infections in irritable bowel syndrome” 2011. CIB
Refereed Journal Articles
* denotes equal first authorship
Campaniello MA, Harrington AM, Martin CM, Blackshaw LA, Brierley SM, Hughes PA (2016) Activation of colo-rectal high-threshold afferent nerves by interleukin-2 is tetrodotoxin-sensitive and upregulated in a mouse model of chronic visceral hypersensitivity. Neurogastroenterol. and Motility. Jan 28(1):54-63
Mikocka-Walus A, Bampton P, Hetzel D, Hughes P, Esterman A, Andrews JM (2015) Cognitive-havaioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial. BMC Gastroenterol. May 2; 15:54
Hughes PA, Moretta M, Lim A, Grasby DJ, Bird D, Brierley SM, Liebregts T, Adam B, Blackshaw LA, Holtmann G, Bampton P, Hoffman P, Andrews JM, Zola H, Krumbiegel D (2014) Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients. Brain, Behaviour and Immunity. Nov 42:191-203. ERA A. IF 6.1. F1000 recommended.
Malsch P, Andratsch M, Vogl C, Link A, Alzheimer C, Brierley SM, Hughes PA, Kress M (2014) Deletion of Interleukin-6 signal transducer gp130 in small sensory neurons attenuates mechanonociception and down-regulates TRPA1. J. Neurosci. Jul 23;34(30):9845-56. ERA A* IF 7.12.
Hughes PA, Castro J, Harrington AM, Isaacs N, Moretta M, Hicks GA, Urso DM, Brierley SM. (2014) Increased κ-opioid receptor expression and function during chronic visceral hypersensitivity. Gut. Jul;63(7):1199-200. ERA A* IF 13.3.
Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, Cohen MB, Macdougall JE, Lavins BJ, Kurtz CB, Silos-Santiago I, Johnston JM, Currie MG, Blackshaw LA, Brierley SM. (2013) Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-c and extracellular cyclic GMP. Gastroenterology. Dec;145(6):1334-46. ERA A* IF 13.9. (Highlighted in Nature Reviews Gastroenterology and Hepatology)
Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Issacs NJ, Maldeniya L, Martin CM, Persson J, Andrews JM, Holtmann G, Blackshaw LA, Brierley SM. (2013) Sensory neuro-immune interactions differ between IBS subtypes. Gut. 62(10):1456-65. ERA A*. IF 13.3 (Highlighted in Nature Reviews Gastroenterology and Hepatology). F1000 recommended
Harrington AM, Brierley SM, Isaacs N, Hughes PA, Castro J, Blackshaw LA (2012) Sprouting of colonic afferent central terminals and increased spinal MAP kinase expression in a mouse model of chronic visceral hypersensitivity. J. Comp. Neurol. 520(10):2241-55. ERA A*. IF 3.9 F1000 recommended
Brierley SM, Castro J, Harrington AM, Hughes PA, Page AJ, Rychkov GY, Blackshaw LA (2011) TRPA1 contributes to specific mechanically activated currents and sensory neuron mechanical hypersensitivity. J. Phys. 589(14):3575-93. ERA A*. IF 4.8
Harrington AM, Hughes PA, Martin CM, Yang J, Castro J, Issacs NJ, Blackshaw LA and Brierley SM (2011) A novel role for TRPM8 in visceral afferent function. Pain 152(7); 1459-68 ERA A. IF 5.35
Brierley SM*, Hughes PA*, Page AJ*, Kwan KY, Martin CM, O’Donnell TA, Cooper NJ, Harrington AM, Adam B, Liebregts T, Holtmann G, Corey DP, Rychkov GY, Blackshaw LA. (2009) The ion channel TRPA1 is required for normal mechanosensation and is modulated by algesic stimuli. Gastroenterology. 137(6);2084-2095. ERA A* IF 12.03 (selected for Faculty of 1000 biology)
Hughes PA*, Brierley SM*, Martin CM, Brookes SJH, Linden DR, Blackshaw LA. (2009) Post inflammatory colonic afferent sensitization: different subtypes, different pathways, and different time-courses. Gut. 58(10):1333-41 ERA A* I.F. 10.6
Hughes PA, Brierley SM, Martin CM, Liebregts T, Adam B, Persson J, Holtmann G, Blackshaw LA. (2009) TRPV1-expressing sensory fibres and IBS: links with immune function. Gut. 58(3): 465-456. ERA A* I.F. 10.6
Brierley SM*, Page AJ*, Hughes PA*, Adam B, Liebregts T, Cooper NJ, Holtmann G, Liedtke W, Blackshaw LA. (2008). Selective Role for TRPV4 Ion Channels in Visceral Sensory Pathways. Gastroenterology. 134(7):2059-69. ERA A* IF 12.03
Lindstrom E, Brusberg M, Hughes PA, Martin CM, Brierley SM, Phillis BD, Martinsson R, Abrahamsson C, Larsson H, Martinez V, Blackshaw LA. (2007). Involvement of metabotropic glutamate 5 receptor in visceral pain. Pain. 137(2):295-305. ERA A I.F. 5.35
Page, AJ, Brierley SM, Martin CM, Hughes PA, Blackshaw LA. (2007). Acid sensing ion channels 2 and 3 are required for inhibition of visceral nociceptors by benzamil. Pain 133 (1-3):150-160. ERA A I.F. 5.35
Hughes PA*, Brierley SM*, Young RL and Blackshaw LA. (2007). Localization and comparative analysis of acid-sensing ion channel (ASIC1, 2, and 3) mRNA expression in mouse colonic sensory neurons within thoracolumbar dorsal root ganglia. J. Comp. Neurol. 500(5):863-75. ERA A* I.F. 3.9
Callaghan PD, Farrand K, Salem A, Hughes P, Daws LC and Irvine RJ. (2006) Repeated administration of the substituted amphetamine p-methoxyamphetamine (PMA) produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine (MDMA). Eur. J. Pharm. 546(1-3):74-81. ERA B I.F. 2.37
De la Lande I, Stepein J, Philpott A, Hughes PA, Stafford I and Horowitz J (2004) Aldehyde dehydrogenase, nitric oxide synthase and superoxide in ex vivo nitrate tolerance in rat aorta. Eur. J. Pharm. 496(1-3):141-149. ERA B I.F. 2.37
Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D Immune activation in Irritable Bowel Syndrome: Can neuroimmune interactions explain symptoms? Am. J. Gastro. 2013 (accepted 28 March 2013). ERA A. I.F. 7.2. F1000 recommended. CME accredited
Brierley SM, Hughes PA, Harrington AM, Rychkov, GY and Blackshaw LA (2010) Identifying the Ion Channels Responsible for Signaling Gastro-Intestinal Based Pain. Pharmaceuticals 3:2768-2798. ERA C. I.F. applied for
Blackshaw LA, Brierley SM, Hughes PA. (2010) TRP channels: new targets for visceral pain. Gut 59(1); 126-135. ERA A* I.F. 10.6
Hughes PA, Blackshaw LA, Brierley SM. (2009) Post inflammatory modification of colonic afferent mechanosensitivity. Clinical and Experimental Pharmacology and Physiology. 36(10):1034-40. ERA B I.F. 2.0
Blackshaw L.A, Brierley S.M, Harrington A.M, and Hughes PA (2013). TRP channels in visceral pain. In: The Open Pain Journal. 6,Suppl 1:M4; 23-30.
Brierley SM, Hughes PA, Harrington AM, Blackshaw LA (2012) Innervation of the gastrointestinal tract by spinal and vagal afferent nerves. In: L.R. Johnson (Ed) Physiology of the Gastrointestinal Tract, 5th Edition. Academic Press, MO, USA. pg703-732.
Hughes PA, Brierley SM, Castro J, Harrington AM, Blackshaw LA (2012) Experimental Colitis Models. In: A Szallasi & T Biro (Eds.) TRP channels in Drug Discovery, Methods in Pharmacology and Toxicology. Springer/Humana Press. DIO 10.1007/978-1-62703-095-3_23
To link to this page, please use the following URL: http://www.adelaide.edu.au/directory/patrick.hughes